Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku gynecologic cancer unit 101 group study)

International Journal of Gynecological Cancer

Volumn 21, Issue 1, 2011, Pages 44-50

  Shoji, Tadahiro ^a   Takatori, Eriko ^a   Omi, Hideo ^a   Kumagai, Seisuke ^a   Yoshizaki, Akira ^a   Yokoyama, Yoshihito ^b   Mizunuma, Hideki ^b   Fujimoto, Toshio ^c   Takano, Tadao ^d   Yaegashi, Nobuo ^d   Tase, Toru ^e   Nakahara, Kenji ^f   Kurachi, Hirohisa ^f   Nishiyama, Hiroshi ^g   Sugiyama, Toru ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Miyagi Cancer Center   (Japan)

^f YAMAGATA UNIVERSITY   (Japan)

^g FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Irinotecan; Oral etoposide; Recurrent ovarian cancer

Indexed keywords

CA 125 ANTIGEN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; PLATINUM; TAXANE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; BODY WEIGHT; CANCER RECURRENCE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL DEPARTMENT; HUMAN; INFORMED CONSENT; LEUKOPENIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 79951495645     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3181ffbe9f     Document Type: Article

References (21)

1. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389-393.
2. Harries M, Gore M. Part II: Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncology. 2002;3:537-545. (Pubitemid 34993641)
3. Gronlund B, Hogdall C, Hansen HH, et al. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol. 2001; 83:123-134.
4. Parmar MK, Ledermann JA, Colombo N, et al and ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OV AR-2.2 trial. Lancet. 2003;361:2099-2106.
5. Gonzalez-Martin AJ, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol. 2005;16:749-755. (Pubitemid 40767095)
6. Pfisterer J, Vergote I, Du Bois A, et al. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15:36-41. (Pubitemid 40696476)
7. Matsumoto K, Katsumata N, Yamanaka Y, et al. The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol. 2006;100:412-416. (Pubitemid 43075278)
8. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma. A Gynecologic Oncology Group Study. J Clin Oncol. 1998;16:405-410. (Pubitemid 28135580)
9. Masumoto N, Nakano S, Esaki T, et al. Sequence-dependent modulation of anticancer drug activities by in an HST-1 human squamous carcinoma cell line. Anticancer Res. 1995;14:405-409.
10. Yamanaka YKN, Watanabe T, Andoh M, et al. A dose finding study of irinotecan in combination with oral etoposide in patients with platinum treated advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol. 2002;21:176[abstract no. 2521].
11. Nishio S, Sugiyama T, Shouji T, et al. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane- resistant epithelial ovarian cancer. Gynecol Oncol. 2007;106:342-347. (Pubitemid 47090189)
12. Rustin GJ, Quinn M, Thigpen T, et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004;96:487-488. (Pubitemid 38443654)
13. Kano Y, Suzuki K, Akustu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J cancer. 1992;50:604-610.
14. Pei XH, Nakanishi Y, Takayama K, et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anti-cancer drugs. 1997;8:231-237. (Pubitemid 27157932)
15. Taron M, Plasencia C, Abad A, et al. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. Invest New Drugs. 2000;18:139-147. (Pubitemid 30261287)
16. Jonsson E, Fridborg H, Nygren P, et al. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol. 1998;54:509-514. (Pubitemid 28487370)
17. Bonner JA, Kozelsky TF. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol. 1996;39:109-112. (Pubitemid 26400668)
18. Gronlund B, Engelholm SA, Horvath G, et al. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study. Cancer. 2005;103:1388-1396. (Pubitemid 40410733)
19. Ratain MJ, Kaminer LS, Bitran JD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced nonYsmall-cell carcinoma of the lung. Blood. 1987;70:1412-1417. (Pubitemid 18026147)
20. Sugita K, Furukawa T, Tsuchida M, et al. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol. 1994;16:384-386.
21. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155-1163.